Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
نویسندگان
چکیده
2015 Single-agent tyrosine kinase inhibitors (TKIs) have significantly improved patient outcomes across multiple tumor subtypes. However, TKI therapy is rarely curative. Early optimism of combining TKIs with cytotoxic chemotherapy failed to produce substantial results in numerous randomized studies. This article highlights potential missteps and improvements in combination therapy thus far, while shedding light on potential improvements for future combinations.
منابع مشابه
Receptor Tyrosine Kinase Inhibitory Activities and Molecular Docking Studies of Some Pyrrolo[2,3-d]pyrimidine Derivatives
In this study, we aimed to determine VEGFR-2, EGFR and PDGFR-β tyrosine kinase inhibitory activities of some pyrrolo[2,3-d]pyrimidine derivatives previously synthesized and showed potent cytotoxic and apoptotic effects against several cancer cell lines by our group and to evaluate the relationships between inhibitory activities and binding properties of the active compounds by molecular docking...
متن کاملMyeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
MPNs including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. JAK2 tyrosine kinase mutation is the most common molecular lesion identified in 90% of cases. JAK2 is involved in EPO signaling pathway, and mutations in it lead to EPO-independent spontaneous phosphorylation. Most tyrosine kinase inhibitors (TKI) a...
متن کاملPromising role of Bruton’s Tyrosine Kinase Inhibitors in Treatment of COVID-19
Severe acute respiratory syndrome coronavirus-2 has led to a widespread pandemic whose spread is astonishing, its treatment is uncertain, mortality is significant, and associated socioeconomic complications are uncontrollable. Although little is known about the pathogenesis of the disease, severe cases of COVID-19 are usually associated with cytokine release syndrome and high serum levels of in...
متن کاملSmall molecule tyrosine kinase inhibitors in pancreatic cancer
Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinase inhibitors represent a newer generation of chemotherapeutic agents targeting specific tumor pathways associated with carcinogenesis including cell cycle control, signal transduction, apoptosis and angiogenesis. These agents prese...
متن کاملCombining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
Recently, with the better understanding of the biology of lung cancer, novel molecular targeted agents have emerged as one of the tools to improve survival and care for patients with non-small-cell lung cancer (NSCLC). Preclinical data have indicated that some targeted agents may be synergistic when combined with chemotherapy. Erlotinib and gefitinib are oral agents that inhibit the intracellul...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014